Approved and marketed nanoparticles for disease targeting and applications in COVID-19

Nano-based systems can be used to transport active medicinal products to specific parts of the body. Most challenges with drug delivery, such as low water solubility and poor bioavailability, can be solved using nanotechnology. In addition, nanoparticles can overcome various physiological obstacles...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Abdellatif Ahmed A. H., Alsowinea Abdullah Fahad
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2021
Materias:	nanoparticle approved marketed drugs liposome polymeric nanoparticles nanocrystal nanoparticles protein-based formulated vaccines Technology T Chemical technology TP1-1185 Physical and theoretical chemistry QD450-801
Acceso en línea:	https://doaj.org/article/70df4239b14a4fbd82958f6f56c88ef5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:70df4239b14a4fbd82958f6f56c88ef5
record_format	dspace
spelling	oai:doaj.org-article:70df4239b14a4fbd82958f6f56c88ef52021-12-05T14:10:58ZApproved and marketed nanoparticles for disease targeting and applications in COVID-192191-909710.1515/ntrev-2021-0115https://doaj.org/article/70df4239b14a4fbd82958f6f56c88ef52021-11-01T00:00:00Zhttps://doi.org/10.1515/ntrev-2021-0115https://doaj.org/toc/2191-9097Nano-based systems can be used to transport active medicinal products to specific parts of the body. Most challenges with drug delivery, such as low water solubility and poor bioavailability, can be solved using nanotechnology. In addition, nanoparticles can overcome various physiological obstacles to increase load distribution to desired sites. Nanoparticles can carry a load of medication or therapeutic agent, such as a DNA-related substance, to enhance distribution time and deliver the drug to the target site in either a nonspecific (through enhanced permeability and retention (EPR)) or specific (through binding specific target receptors) manner. Moreover, nanoparticle drug delivery systems have been employed in the clinic since the early 1990s. Since then, the field of nanomedicine has developed with growing technical needs to improve the delivery of various medications. Over these past decades, newer generations of nanoparticles have emerged that are capable of conducting new delivery activities that could enable therapy via innovative therapeutic modalities. This review highlights different types of approved and currently marketed nanoparticles, such as nanocrystals, liposomes, lipid nanoparticles, PEGylated polymeric nanoparticles, protein-based nanoparticles, and metal-based nanoparticles. Furthermore, it explores the use of vaccine-loaded nanoparticles for COVID-19 prophylaxis.Abdellatif Ahmed A. H.Alsowinea Abdullah FahadDe Gruyterarticlenanoparticleapproved marketed drugsliposomepolymeric nanoparticlesnanocrystal nanoparticlesprotein-basedformulated vaccinesTechnologyTChemical technologyTP1-1185Physical and theoretical chemistryQD450-801ENNanotechnology Reviews, Vol 10, Iss 1, Pp 1941-1977 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	nanoparticle approved marketed drugs liposome polymeric nanoparticles nanocrystal nanoparticles protein-based formulated vaccines Technology T Chemical technology TP1-1185 Physical and theoretical chemistry QD450-801
spellingShingle	nanoparticle approved marketed drugs liposome polymeric nanoparticles nanocrystal nanoparticles protein-based formulated vaccines Technology T Chemical technology TP1-1185 Physical and theoretical chemistry QD450-801 Abdellatif Ahmed A. H. Alsowinea Abdullah Fahad Approved and marketed nanoparticles for disease targeting and applications in COVID-19
description	Nano-based systems can be used to transport active medicinal products to specific parts of the body. Most challenges with drug delivery, such as low water solubility and poor bioavailability, can be solved using nanotechnology. In addition, nanoparticles can overcome various physiological obstacles to increase load distribution to desired sites. Nanoparticles can carry a load of medication or therapeutic agent, such as a DNA-related substance, to enhance distribution time and deliver the drug to the target site in either a nonspecific (through enhanced permeability and retention (EPR)) or specific (through binding specific target receptors) manner. Moreover, nanoparticle drug delivery systems have been employed in the clinic since the early 1990s. Since then, the field of nanomedicine has developed with growing technical needs to improve the delivery of various medications. Over these past decades, newer generations of nanoparticles have emerged that are capable of conducting new delivery activities that could enable therapy via innovative therapeutic modalities. This review highlights different types of approved and currently marketed nanoparticles, such as nanocrystals, liposomes, lipid nanoparticles, PEGylated polymeric nanoparticles, protein-based nanoparticles, and metal-based nanoparticles. Furthermore, it explores the use of vaccine-loaded nanoparticles for COVID-19 prophylaxis.
format	article
author	Abdellatif Ahmed A. H. Alsowinea Abdullah Fahad
author_facet	Abdellatif Ahmed A. H. Alsowinea Abdullah Fahad
author_sort	Abdellatif Ahmed A. H.
title	Approved and marketed nanoparticles for disease targeting and applications in COVID-19
title_short	Approved and marketed nanoparticles for disease targeting and applications in COVID-19
title_full	Approved and marketed nanoparticles for disease targeting and applications in COVID-19
title_fullStr	Approved and marketed nanoparticles for disease targeting and applications in COVID-19
title_full_unstemmed	Approved and marketed nanoparticles for disease targeting and applications in COVID-19
title_sort	approved and marketed nanoparticles for disease targeting and applications in covid-19
publisher	De Gruyter
publishDate	2021
url	https://doaj.org/article/70df4239b14a4fbd82958f6f56c88ef5
work_keys_str_mv	AT abdellatifahmedah approvedandmarketednanoparticlesfordiseasetargetingandapplicationsincovid19 AT alsowineaabdullahfahad approvedandmarketednanoparticlesfordiseasetargetingandapplicationsincovid19
_version_	1718371544425562112

Approved and marketed nanoparticles for disease targeting and applications in COVID-19

Ejemplares similares